Phase 3 data show DOR/ISL matches standard INSTI-based therapy in efficacy and safety, signaling a potential shift in first-line HIV treatment.
From Viral Architecture to Clinical Impact: Defining the Next Era of HIV Treatment
Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.
DOR/ISL exemplifies how 2-drug regimens could meet the complex needs of an aging HIV population.
Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.
Long-acting CAB+RPV may maintain efficacy even with delayed injections, offering real-world flexibility.
Long-acting therapies could be key to engaging unsuppressed patients and closing persistent gaps in HIV care.
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH
2
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
3
Rituximab Matches Ocrelizumab in Head-to-Head MS Trial
4
5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care
5